I'm initiating SELLAS Life Sciences (SLS) with a "Hold" rating. The reason why I'm giving this biotech this rating is because it is in the process of developing its WT1-targeting immunotherapeutic ...

Document that the AML program is effective, risk based, and reasonably designed. Maintain separate documentation of program design and execution. Draft clear descriptions of the roles and ...

But after speaking with compliance professionals across banking and fintech, another challenge repeatedly appears in practice: not detection itself, but coordination around the decision. Many AML ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help ...

Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. With relapse rates as high as 50%, routine measurable residual disease (MRD) ...

The alternative text for this image may have been generated using AI. For the launch of venetoclax in China in December 2020, the maximum follow-up duration was 48 months. Due to the relatively low ...

The open-label, single-arm trial studying Sellas’ small molecule met all primary endpoints. (iStock / Getty Images Plus) Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage ...